Highlights

  • Dimerix (ASX:DXB) has secured access to a A$34 million non-dilutive Loan Facility rather than receiving the full amount upfront.
  • The facility is intended to support completion of the ACTION3 Phase 3 trial and the planned Phase 2 development of DMX-652.
  • Interest is charged at 10% per annum on drawn amounts, while lenders also receive participation in certain future DMX-200 milestone payments.
  • Trial progress, drawdowns, funding costs and remaining approval conditions are the main areas to watch.

Dimerix (ASX:DXB) has strengthened its funding position through a A$34 million non-dilutive loan facility designed to support its kidney disease development programs.

The distinction is important: the company has secured access to Debt funding, not received the full A$34 million as cash upfront. The commercial benefit is reduced immediate Equity dilution, while the trade-off is interest expense and a share of future milestone payments if DMX-200 progresses successfully.

What was announced, and when

In early September 2026, Dimerix (ASX:DXB) announced that it had secured a A$34 million non-dilutive funding facility.

The company is developing treatments for inflammatory kidney and respiratory diseases.

Its lead asset, DMX-200, is being evaluated in ACTION3, a global Phase 3 study targeting focal segmental glomerulosclerosis, a rare kidney disease involving scarring of the kidney’s filtering structures.

Dimerix is also preparing DMX-652 for a planned Phase 2 study in acute kidney injury.

The funding arrangement is intended to provide additional financial flexibility across both programs.

The terms behind the number

The facility is structured in two broad components.

Approximately A$17 million is required to be drawn by mid-September 2026.

A further A$17 million is available at the company’s discretion until the end of March 2027, subject to the facility terms remaining satisfied.

Dimerix also has the option to expand the facility to A$50 million before that date, although the company has indicated that it does not currently intend to use that additional capacity.

Interest is charged at 10% per annum on amounts actually drawn and compounds annually.

The facility matures in January 2028.

Early repayment is permitted, with interest reduced proportionally where applicable.

The milestone participation structure

The funding comes with an additional economic component beyond principal and interest.

Lenders are entitled to 30% of aggregate milestone payments received under DMX-200 commercial licence agreements.

This participation is capped at twice the amount drawn under the facility.

If Dimerix were to draw the full A$34 million, the maximum milestone participation would therefore be capped at A$68 million.

That payment would come from future partner milestone receipts rather than from existing cash.

The structure means the facility reduces immediate equity dilution but gives lenders exposure to potential future commercial success from DMX-200.

Why it matters commercially

Dimerix (ASX:DXB) reported cash of approximately A$16.2 million at 30 June 2026.

The company has already licensed DMX-200 across five territories and reported upfront payments exceeding A$80 million.

It has also outlined potential future milestone payments of approximately A$1.9 billion across those agreements, in addition to royalties.

Dimerix has said that the new facility, together with existing cash, is expected to fund completion of ACTION3 and support the planned DMX-652 Phase 2 program.

For a clinical-stage biotechnology company, avoiding an immediate equity raising can help preserve the existing capital structure.

However, debt shifts the funding burden elsewhere.

Interest accrues regardless of clinical outcomes, while milestone participation reduces the amount Dimerix could ultimately retain from successful licensing events.

Debt changes the risk profile

Debt financing introduces risks that differ from equity funding.

Dimerix remains a clinical-stage company without an established Operating Revenue base capable of servicing debt in the conventional sense.

Interest continues to accrue on drawn amounts whether or not clinical programs deliver favourable results.

Most lenders under the facility hold a General Security Deed over Assets of Dimerix and its subsidiaries.

The loans associated with SKIPTAN Pty Ltd and the P&M Meurs family trust remain unsecured pending an ASX Waiver or Shareholder approval.

That remains an outstanding condition worth monitoring.

The facility also includes standard default provisions covering matters such as insolvency, material adverse change and breach of contractual obligations.

The second Tranche should also be viewed as available funding rather than cash already received.

ACTION3 remains central

The value of the facility ultimately depends heavily on the progress of DMX-200.

The ACTION3 Phase 3 trial is fully recruited, with 333 adults randomised against a target of at least 286 participants.

A blinded interim futility assessment at 72 patients indicated that DMX-200 was performing better than placebo.

However, that assessment was blinded and interim.

It should not be interpreted as definitive efficacy evidence.

The final analysis is based on urinary protein-creatinine ratio after 104 weeks.

That endpoint remains the more important clinical milestone because the commercial potential of DMX-200 and the value of existing licensing arrangements depend on the trial producing a sufficiently supportive outcome.

What to watch

The first item is confirmation of the initial facility drawdown.

The second is resolution of the related-party security arrangements involving the SKIPTAN entities.

The third is quarterly cash expenditure relative to the 10% interest cost.

The fourth, and most important, is the ACTION3 outcome.

For Dimerix (ASX:DXB), the A$34 million facility extends the funding runway while limiting immediate equity dilution. But it does so by adding debt obligations and sharing part of future milestone economics. The success of that trade-off ultimately depends on whether DMX-200 progresses as planned.